Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: Inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors

Journal of Medicinal Chemistry

Volumn 46, Issue 18, 2003, Pages 3822-3839

  Campiani, Giuseppe ^a   Butini, Stefania ^a   Trotta, Francesco ^a   Fattorusso, Caterina ^b   Catalanotti, Bruno ^b   Aiello, Francesca ^c   Gemma, Sandra ^a   Nacci, Vito ^a   Novellino, Ettore ^b   Stark, Jennifer Ann ^d   Cagnotto, Alfredo ^e   Fumagalli, Elena ^e   Carnovali, Francesco ^e   Cervo, Luigi ^e   Mennini, Tiziana ^e  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF CALABRIA   (Italy)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA ADRENERGIC RECEPTOR; BP 897; COCAINE; DICHLOROPHENYLPIPERAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HALOPERIDOL; HETEROCYCLIC COMPOUND; LIGAND; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL] 1,2,3,4 TETRAHYDROPYRAZINO[1,2 A]INDOL 1(2H) ONE; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL]BENZO[B]FURAN 2 CARBOXAMIDE; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL]INDOLE 2 CARBOXAMIDE; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL]ISOQUINOLINE 3 CARBOXAMIDE; N [4 [4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL]QUINOLINE 2 CARBOXAMIDE; N [4 [4 (2,4 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL] 5 CHLOROINDOLE 2 CARBOXAMIDE; N [4 [4 (2,4 DICHLOROPHENYL)PIPERAZIN 1 YL]BUTYL]INDOLE 2 CARBOXAMIDE; PIPERAZINE DERIVATIVE; PRAZOSIN; QUINPIROLE; RECEPTOR SUBTYPE; SEROTONIN RECEPTOR; SPIPERONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BINDING ASSAY; BIOLOGY; COCAINE DEPENDENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR MODEL; NONHUMAN; RAT; RECEPTOR AFFINITY; STIMULUS; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ADDICTIVE; BRAIN; COCAINE; COCAINE-RELATED DISORDERS; CONDITIONING, OPERANT; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; EXTINCTION, PSYCHOLOGICAL; LIGANDS; MALE; MODELS, MOLECULAR; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SELF ADMINISTRATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0042921579     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0211220     Document Type: Article

References (54)

1. Carrol, F. I.; Howell, L. L.; Kuhar, M. J. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J. Med. Chem. 1999, 42, 2721-2736.
2. Substance Abuse and Mental Health Services Administration National Household Survey on Drug Abuse: Main Findings, 1997; Department of Health and Human Services: Washington, DC, 1998.
3. Schuster, C. R.; Kuhar, M. J. Pharmacological Aspects of Drug Dependence: Toward an Integrated Neurobehavioral Approach. Springer-Verlag: New York, 1996; Vol. 118.
4. Woolverton, W. L.; Ranaldi R.; Wang, Z.; Ordway G. A.; Paul I. A.; Petukhov P.; Kozikowski, A. Reinforcing strength of a novel dopamine transporter ligand: pharmacodynamic and pharmacokinetic mechanisms. J. Pharmacol. Exp. Ther. 2002, 303, 211-217.
5. Gawin, F. H.; Kleber, H. D. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch. Gen. Psychiatry 1986, 43, 107-113.
6. Rohsenow, D. J.; Niaura, R. S.; Childress, A. R.; Abrams, D. B.; Monti, P. M. Cue reactivity in addictive behaviors: theoretical and treatment implications. Int. J. Addict. 1990, 25, 957-993.
7. Gawin, F. H. Cocaine addiction: psychology and neurophysiology. Science 1991, 251, 1580-1586.
8. Wikler, A. Dynamics of drug dependence. Arch. Gen. Psychiatry 1973, 28, 611-616.
9. O'Brien, C. P.; Childress, A. R.; McLellan, A. T.; Ehrman, R. A learning model of addiction. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 1992, 70, 157-177.
10. O'Brien, C. P.; McLellan, A. T. Myths about the treatment of addiction. Lancet 1996, 347, 237-240.
11. De Wit, H.; Stewart, J. Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology 1981, 75, 134-143.
12. Meil, W. M.; See, R. E. Lesions of the basolateral amygdala abolish the ability of drug associated cues to reinstate responding during withdrawal from self-administered cocaine. Behav. Brain Res. 1997, 87, 139-148.
13. Weiss, F.; Maldonado-Vlaar, C. S.; Parsons, L. H.; Kerr, T. M.; Smith, D. L.; Ben-Shahar, O. Control of cocaine-seeking behavior by drug-associated stimuli in rats: effects on recovery of extinguished operant-responding and extracellular dopamine levels in amygdala and nucleus accumbens. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 4321-4326.
14. Whitelaw, R. B.; Markou, A.; Robbins, T. W.; Everitt, B. J. Excitotoxic lesions of the basolateral amygdala impair the acquisition of cocaine-seeking behavior under a second schedule of reinforcement. Psychopharmacology 1996, 127, 213-224.
15. Di Ciano, P.; Blaha, C. D.; Phillips, A. G. Conditioned changes in dopamine oxidation currents in the nucleus accumbens of rat by stimuli paired with self-administration or yoked-administration of D-amphetamine. Eur. J. Neurosci. 1998, 10, 1121-1127.
16. Ito, R.; Dalley, J. W.; Howes, S. R.; Robbins, T. W.; Everitt, B. J. Dissociation in conditioned dopamine release in the nucleus accumbens core and shell in response to cocaine cues and during cocaine-seeking behavior in rats. J. Neurosci. 2000, 20, 7849-7495.
17. Spealman, R. D. Antagonism of behavioural effects of cocaine by selective dopamine receptor blockers. Psychopharmacology 1990, 101, 142-145.
18. (b) Howell, L. L.; Byrd, L. D. Enhanced sensitivity to the behavioural effects of cocaine by selective dopamine receptor blockers. J. Pharmacol. Exp. Ther. 1992, 262, 907-915.
19. 2 dopamine receptors. Neuro psychopharmacology 2003, 28, 1150-1159.
20. 3 receptor agonist. Nature 1999, 400, 371-375.
21. 3 receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 2000, 294, 1154-1165.
22. 3 receptor antagonist. Soc. Neurosci. Abstr. 2001, 27, 647-649.
23. 3 receptor partial agonist, BP897, is a potent ligand at diverse adrenergic and serotoninergic receptors. Soc. Neurosci. Abstr. 2000, 26, 808-809.
24. These results were partially presented at the XIII° Meeting of the Italian Society of Neuropsychopharmacology: Novel frontieres in neuropsychopharmacology: from genome to therapy, Milan, 9-12 July 2002; Carnovali, F.; Campiani, G.; Butini, S.; Aiello, F.; Trotta, F.; Stark, J.; Cagnotto, A.; Mennini, T.; Cervo, L. Controllo dei comportamenti di ricerca della cocaina dovuti agli stimoli precedentemente associati nei ratti: c'e' coinvolgimento dei recettori D3?, P-41, 402.
25. These results were partially presented at the XIII° Meeting of the Italian Society of Neuropsychopharmacology: Novel frontieres in neuropsychopharmacology: from genome to therapy, Milan, 9-12 July 2002; Carnovali, F.; Campiani, G.; Butini, S.; Aiello, F.; Trotta, F.; Stark, J.; Cagnotto, A.; Mennini, T.; Cervo, L. Controllo dei comportamenti di ricerca della cocaina dovuti agli stimoli precedentemente associati nei ratti: c'e' coinvolgimento dei recettori D3?, P-41, 402.
26. 3 receptor antagonists and partial agonists. J. Med. Chem. 2002, 45, 4594-4597.
27. 3 receptor ligands. J. Med. Chem. 2002, 45, 5727-5735.
28. Wolfe, J. P.; Buchwald, S. L. Scope and limitations of the Pd/BINAP-catalyzed amination of aryl bromides. J. Org. Chem. 2000, 65, 1144-1157.
29. Crescenza, A.; Botta, M.; Corelli, F.; Santini, A.; Tafi, A. Cyclic dipeptides. Synthesis of methyl (R)-6-[(tert-butoxycarbonyl)-amino]-4,5,6,7-tetrahydro-2-methyl-5-oxo-1, 4-thiazepine-3-carboxylate and its hexahydro analogues: elaboration of a novel ACE/NEP inhibitor. J. Org. Chem. 1999, 64, 3019-3025.
30. Nagarajan, K.; Ranga Rao, V.; Venkateswarlu, A. Condensed heterotricycles: pyrrolo[1,2-α]quinoxaline derivatives. Indian J. Chem. 1972, 10, 344-350.
31. Tarver, J. E., Jr.; Pfizenmayer, A. J.; Joullié, M. M. Total syntheses of conformationally constrained didemnin B analogues. Replacements of N,O-dimethyltyrosine with L-1,2,3,4-tetrahydroisoquinoline and L-1,2,3,4-tetrahydro-7-methoxyisoquinoline. J. Org. Chem. 2001, 66, 7575-7587.
32. Verheyden, J. P. H.; Moffatt, J. G. Halo sugar nucleosides. Reactions for the chlorination and bromination of nucleoside hydroxyl groups. J. Org. Chem. 1972, 37, 2289-2299.
33. McKillop, A.; Taylor, R. J. K.; Watson, R. J.; Lewis, N. An improved procedure for the preparation of the Garner aldehyde and its use for the synthesis of N-protected 1-halo-2-(R)-amino-3-butenes. Synthesis 1994, 1, 31-33.
34. 2 antagonist properties. J. Med. Chem. 2001, 44, 186-197.
35. Rajur, S. B.; Merwade A. Y.; Flendi S. B.; Basanagoudar I. D. Synthesis of 1,2,3,4-tetrahydropyrazino[1,2-a]indoles and ethyl 1-(2-amino-ethyl)indole-2-carboxylates. Indian J. Chem. 1989, 28B, 1065-1068.
36. Heinzman, S. W.; Ganem, B. Mechanism of sodium borohydride-cobaltous boride reductions. J. Am. Chem. Soc. 1982, 104, 6801-6802.
37. 1A receptor ligands. Med. Chem. Res. 1993, 3, 249-256.
38. Einsiedel, J.; Thomas, C.; Hübner, H.; Gmeiner, P. Phenyloxazoles and phenylthiazoles as benzamide bioisosteres: synthesis and dopamine receptor binding profiles. Bioorg. Med. Chem. Lett. 2000, 10, 2041-2044.
39. Everitt, B. J.; Wolf, M. E. Psychomotor stimulant addiction: a neural systems perspective. J. Neurosci. 2002, 22, 3312-3320.
40. 1A receptor antagonist. Behav. Brain Res. 1996, 73, 337-353.
41. Campiani, G.; Nacci, V.; Bechelli, S.; Ciani, S.; Garofalo, A.; Fiorini, I.; Wikstrom, H. V.; de Boer, P.; Tepper, P. G.; Cagnotto, A.; Mennini, T. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]-benzothiazepine structure. J. Med. Chem. 1998, 41, 3763-3772.
42. Claudi, F.; Di Stefano, A.; Napolitani, F.; Cingolani, G. M.; Giorgioni, G.; Fontenla, J. A.; Montenegro, G. Y.; Rivas, M. E.; Rosa, E.; Michelotto, B.; Orlando, G.; Brunetti, L. Binding and preliminary evaluation of 5-hydroxy- and 10-hydroxy-2,3,12,12a-tatrahydro-1H-[1]benzoxepino[2,3,4-ij]isoquinoline as dopamine receptors ligands. J. Med. Chem. 2000, 43, 599-608.
43. 1A receptor. Synthesis and structure-affinity relationships. Eur. J. Med. Chem. 2000, 35(7-8), 677-689.
44. 3H]RX-821002 binding to membrane and tissue sections. Eur. J. Pharm. 1996, 310, 83-93.
45. 35S]-GTPγS binding in rat hippocampal membranes. Eur. J. Pharmacol. 1998, 343, 303-312.
46. 3 dopamine receptor. Neurosci. Lett. 1997, 226, 91-94.
47. De Lean, K. W.; Munson, P. J.; Rodbard, D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay and physiological dose-response curves. Am. J. Physiol. 1978, 235, E97-E102.
48. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
49. Caine, S. B.; Lintz, R.; Koob, G. F. Intravenous drug self-administration techniques in animals. In Behavioral Neuroscience: A Practical Approach; Sahgal, E. A., Ed; Oxford IRL Press: Oxford, 1993; pp 117-143.
50. Maple, J. R.; Diniur, U.; Hagler, A. T. Derivation of force fields for molecular mechanics and dynamics from ab initio energy surfaces. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 5350-5354.
51. 3 Receptor Subtype. J. Med. Chem. 1997, 40, 833-840.
52. Fletcher, R. Unconstrained Optimization. In Practical Methods of Optimization; John Wiley & Sons: New York, 1980; Vol. 1.
53. (a) Stewart, J. J. P. MOPAC: A Semiempirical Molecular Orbital Program J. Comput.-Aided Mol. Des. 1990, 4, 1-105.
54. (b) Stewart, J. J. P. MOPAC MANUAL, 6th ed.; 1990.